Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.
   PubMed Web of Science ®Google Scholar
• Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729–37.
   PubMed Web of Science ®Google Scholar
• Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441–7.
   PubMed Web of Science ®Google Scholar
• Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 1999;35:1059–64.
   PubMed Web of Science ®Google Scholar
• Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD. Ann Oncol 2000;11:837–43.
   PubMed Web of Science ®Google Scholar
• Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, et al. Adjuvant chemotherapy in gastric caucer: a meta-analysis of randomized trials and a comparison will previous meta-analyses. Tumori 2002;88:21–7.
   PubMed Web of Science ®Google Scholar
• Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983;52:1105–12.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 1978;16:209–16.
   PubMedGoogle Scholar
• Huguier M, Destroyes JP, Baschet C, Le Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection. Am J Surg 1980;139:197–9.
   PubMed Web of Science ®Google Scholar
• Blake JR, Hardcastle JD, Wilson RG. Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. Clin Oncol 1981;7:13–27.
   PubMed Web of Science ®Google Scholar
• Schlag P, Schreml W, Gaus W, Herfarth C, Linder MM, Queisser W, et al. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 1982;80:277–83.
   PubMedGoogle Scholar
• Alcobendas F, Mala A, Estape J, Curto J, Pera C. Mitomycin-C as an adjuvant in resected gastric cancer. Ann Surg 1983;198:13–17.
   PubMed Web of Science ®Google Scholar
• Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer 1983;52:1105–12.
   PubMed Web of Science ®Google Scholar
• Douglass HO, Stablein DM, Bruckner HW, O'Connell MJ, Livstone EM, Mayer RJ, et al. Controlled trial of adjuvant chemo-therapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1982;49:1116–22.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984;2:1366–71.
   PubMed Web of Science ®Google Scholar
• Engstrom PF, Lavin PT, Douglass HO Jr, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancel patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985;55:1868–73.
   PubMed Web of Science ®Google Scholar
• Jakesz R, Dittrich C, Funovics J, Hofbauer F, Rainer H, Reiner G, et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 1988;110:44–51.
   PubMedGoogle Scholar
• Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1989;1:571–4.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Chilvers CE, Amadori D, Medi F, Fountzilas G, Rauschecker H, et al. Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann Oncol 1994;5:33–6.
   PubMed Web of Science ®Google Scholar
• Maehara Y, Moriguchi S, Sakaguchi Y, Emi Y, Kohnoe S, Tsujitani S, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990;45:169–72.
   PubMed Web of Science ®Google Scholar
• Estape J, Grau JJ, Alcobendas F, Curto J, Daniels M, Viñolas N, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991;213:219–21.
   PubMed Web of Science ®Google Scholar
• Krook JE, O'Connell MJ, Wieand HS, Beart RW Jr, Leigh JE, Kugler JW, et al. A prospective randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin us surgical adjuvant chemotherapy for reseeted gastric cancer. Cancer 1991;67:2454–8.
   PubMed Web of Science ®Google Scholar
• Grau JJ, Estapé J, Alcobendas F, Pera C, Daniels M, Terés J. Positive results of adjuvant mitomycin-C in rcsccted gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993;29:340–2.
   Google Scholar
• Chou FF, Sheen Chen SM, Liu PP, Chen FC. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J Surg Oncol 1994;57:239–42.
   PubMed Web of Science ®Google Scholar
• Lise M, Nitti D, Marcher A, Sahmoud T, Buyse M, Duez N, et al. Final results of a phase III clinical trial of aduvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995;13:2757–63.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, et al. Adjuvant chemo-therapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adeno-carcinoma: a Southwest Oncology Group study. Ann Surg Oncol 1995;2:488–94.
   PubMed Web of Science ®Google Scholar
• Neri B, de Leonardis V, Romano S, Andreoli F, Pernice LM, Bruno L, et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multi-centre randomized study. Br J Cancer 1996;73:549–52.
   PubMed Web of Science ®Google Scholar
• Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810–15.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999;354:273–7.
   PubMed Web of Science ®Google Scholar
• Bresciani C, Gama-Rodrigues J, Strassmann V, Waitzberg DL, Matsuda M, Pinotti HW. Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. Rev Hosp Clin Fac Med Sao Paulo 2001;55:129–36.
   Google Scholar
• Neri B, Cini G, Andreoli G, Boffi B, Francesconi D, Mazzanti R, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001;84:878–80.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002;13:299–307.
   PubMed Web of Science ®Google Scholar
• Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer. Jpn Clin Oncol 2003;21:2282–7.
   PubMed Web of Science ®Google Scholar
• Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004;187:440–5.
   PubMed Web of Science ®Google Scholar
• Uslu A, Karaca C, Nari A, Adagülü H, Aykas A, Gürkan A, et al. Adjuvant chemotherapy in a unique population of patients with gastric cancer undergoing surgery. Hepatogastroenterology 2004;51:1245–8.
   PubMedGoogle Scholar
• Bouché O, Ychou M, Burtin P, Bedenne L, DucreuxM, Lebreton G, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase HI trial (8801). Ann Oncol 2006;16:1488–97.
   Web of Science ®Google Scholar
• Petrioli R, Sabatino M, Roviello F, Marrelli D, Nastri G, Marsili S, et al. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. Hepatogastroenterology 2005;52:1626–30.
   PubMedGoogle Scholar
• Nitti D, Wils J, Dos Santos G, Fountzilas G, Conte PF, Sava C, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006;17:262–9.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg Soc 2007;94:1468–76.
   PubMed Web of Science ®Google Scholar
• De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 2007;18:1354–8.
   PubMed Web of Science ®Google Scholar
• Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008;100:388–98.
   PubMedGoogle Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–20.
   PubMed Web of Science ®Google Scholar
• Ha TK, Jung MS, Lee KH, Lee KG, Kwon SJ. The effect of adjuvant chemotherapy on stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer. Cancer Res Treat 2009;41:19–23.
   PubMed Web of Science ®Google Scholar
• Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, et al. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment ofgastric cancer: a phase III randomized, multicenter, clinical trial. Oncology 2010;78:54–61.
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4348–55.
   PubMed Web of Science ®Google Scholar
• Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer 2011;14:212–18.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label,randomised controlled trial. Lancet 2012;379:315–21.
   PubMed Web of Science ®Google Scholar
• Okuyama T, Korenaga D, Edagawa A, Itoh S, Oki E, Kawanaka H, et al. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surg Today 2012;42:734–40.
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–50.
   PubMed Web of Science ®Google Scholar
• Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727–32.
   PubMed Web of Science ®Google Scholar
• Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767–73.
   PubMed Web of Science ®Google Scholar